278 related articles for article (PubMed ID: 16763282)
1. Systemic therapy in the palliative management of advanced salivary gland cancers.
Laurie SA; Licitra L
J Clin Oncol; 2006 Jun; 24(17):2673-8. PubMed ID: 16763282
[TBL] [Abstract][Full Text] [Related]
2. Systemic therapies for recurrent and/or metastatic salivary gland cancers.
Vattemi E; Graiff C; Sava T; Pedersini R; Caldara A; Mandarà M
Expert Rev Anticancer Ther; 2008 Mar; 8(3):393-402. PubMed ID: 18366287
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
5. Management of minor salivary gland carcinomas.
Eschwege F
Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):631-2. PubMed ID: 8655391
[No Abstract] [Full Text] [Related]
6. Phase II study of gefitinib in patients with advanced salivary gland cancers.
Jakob JA; Kies MS; Glisson BS; Kupferman ME; Liu DD; Lee JJ; El-Naggar AK; Gonzalez-Angulo AM; Blumenschein GR
Head Neck; 2015 May; 37(5):644-9. PubMed ID: 24585506
[TBL] [Abstract][Full Text] [Related]
7. Salivary gland cancers: biology and molecular targets for therapy.
Bell D; Hanna EY
Curr Oncol Rep; 2012 Apr; 14(2):166-74. PubMed ID: 22246609
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target.
Yeoh CC; Dabab N; Rigby E; Chhikara R; Akaev I; Gomez RS; Fonseca F; Brennan PA; Rahimi S
J Oral Pathol Med; 2018 Aug; 47(7):691-695. PubMed ID: 29863801
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Agulnik M; Cohen EW; Cohen RB; Chen EX; Vokes EE; Hotte SJ; Winquist E; Laurie S; Hayes DN; Dancey JE; Brown S; Pond GR; Lorimer I; Daneshmand M; Ho J; Tsao MS; Siu LL
J Clin Oncol; 2007 Sep; 25(25):3978-84. PubMed ID: 17761983
[TBL] [Abstract][Full Text] [Related]
10. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
Falchook GS; Lippman SM; Bastida CC; Kurzrock R
Head Neck; 2014 Mar; 36(3):E25-7. PubMed ID: 23852769
[TBL] [Abstract][Full Text] [Related]
11. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
[TBL] [Abstract][Full Text] [Related]
12. Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine.
Haddad R; Posner MR
Clin Adv Hematol Oncol; 2003 Apr; 1(4):226-8. PubMed ID: 16224411
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group.
Gilbert J; Li Y; Pinto HA; Jennings T; Kies MS; Silverman P; Forastiere AA
Head Neck; 2006 Mar; 28(3):197-204. PubMed ID: 16470745
[TBL] [Abstract][Full Text] [Related]
14. Systemic therapy in the management of metastatic or advanced salivary gland cancers.
Lagha A; Chraiet N; Ayadi M; Krimi S; Allani B; Rifi H; Raies H; Mezlini A
Oral Oncol; 2012 Oct; 48(10):948-957. PubMed ID: 22698431
[TBL] [Abstract][Full Text] [Related]
15. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review.
Laurie SA; Ho AL; Fury MG; Sherman E; Pfister DG
Lancet Oncol; 2011 Aug; 12(8):815-24. PubMed ID: 21147032
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer.
Debaere D; Vander Poorten V; Nuyts S; Hauben E; Schoenaers J; Schöffski P; Clement PM
B-ENT; 2011; 7(1):1-6. PubMed ID: 21563549
[TBL] [Abstract][Full Text] [Related]
17. Salivary gland cancers: current treatments, molecular characteristics and new therapies.
Chandana SR; Conley BA
Expert Rev Anticancer Ther; 2008 Apr; 8(4):645-52. PubMed ID: 18402531
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for salivary gland cancer.
Kaplan MJ; Johns ME; Cantrell RW
Otolaryngol Head Neck Surg; 1986 Sep; 95(2):165-70. PubMed ID: 3035459
[TBL] [Abstract][Full Text] [Related]
19. Epithelial tumors of the lacrimal glands: a clinicopathologic study.
Paulino AF; Huvos AG
Ann Diagn Pathol; 1999 Aug; 3(4):199-204. PubMed ID: 10459045
[TBL] [Abstract][Full Text] [Related]
20. Carcinoma of the salivary glands: guidelines and case report of sustained remission with docetaxel.
Arrondeau J; Le Nagat S; Lefèvre M; Tassart M; Touboul E; Lacau St Guily J; Huguet F
J Clin Pharm Ther; 2015 Feb; 40(1):116-8. PubMed ID: 25302593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
